Pure Global
NCT06283147

Risk Assessment and Management Program (RAMP) on Knee Osteoarthritis in Primary Care

Risk Assessment and Management Program (RAMP) on Knee Osteoarthritis in Primary Care- a One-year Pragmatic Randomized Controlled Trial
Chinese University of Hong Kong·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Knee Osteoarthritis
Drug/Device/Intervention
Risk assessment and Management Programme - Knee Osteoarthritis
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Chinese University of Hong Kong
Location
Hong Kong, China
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Apr 01, 2026
Enrollment
228 participants
Primary outcome

Knee pain

Summary

The goal of this clinical trial is to determine the clinical effectiveness of a Chronic Care
 Model (CCM) named Risk Assessment and Management Program on Knee OA (RAMP-Knee OA) in adults
 with knee Osteoarthritis (Knee OA) at 52 weeks.
 
 Participants will be screened for eligibility to participate. After confirming eligibility,
 participants will complete the baseline assessment and be randomized into one of the
 following groups (n=114 for each group):
 
 1. RAMP Knee-OA group
 
 2. Usual care group
 
 Outcomes will be measured at baseline, week 16, week 32, and week 52.

ICD-10 classifications
Chronic instability of kneeGonarthrosis [arthrosis of knee]Other hypertrophic osteoarthropathyDislocation, sprain and strain of joints and ligaments of kneePatellofemoral disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06283147
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06283147 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese University of Hong Kong and is currently Recruiting. The study focuses on Knee Osteoarthritis. Target enrollment is 228 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.